To assess the efficacy and safety of icodextrin in Japanese patients and to investigate the relationship between net ultrafiltration (UF) during the long dwell and plasma oligosaccharides.
♦ Design
Open-labeled clinical trial involving patients on continuous ambulatory peritoneal dialysis (CAPD) receiving icodextrin during the 12-hour long dwell for 6 weeks, preceded by and followed by a 2-week baseline period and a follow-up period during which 1.36% glucose was used for the 8-hour long dwell.
♦ Setting
A prospective, randomized multicenter study done in tertiary medical centers.
♦ Patients
18 stable patients on CAPD for 3 months or longer.
♦ Main Outcomes Measures
Net UF (in milliliters), UF rate (in milliliters per hour), plasma oligosaccharides, serum osmolarity (in milliosmoles per liter), peritoneal absorption of icodextrin, and peritoneal clearances of icodextrin, creatinine, and urea were assessed. Adverse events, laboratory findings, and vital signs were also monitored.
♦ Results
Long-dwell net UF (544.4 ± 96.7 mL at day 3, p < 0.001; 309.4 ± 60.7 mL at week 4, p < 0.001; and 391.7 ± 61.1 mL at week 6, p< 0.001) and UF rate (48.2 ± 38.8 mL/hour at day 3, p < 0.001; 26.9 ± 22.1 mL/hr at week 4, p < 0.002; and 35.3 ± 22.9 mL/hr at week 6, p = 0.0002) were significantly greater during the icodextrin period than at baseline (-25.9 ± 46.0 mL and -2.2 ± 22.1 mL/hr, respectively). Plasma oligosaccharides reached steady state within 2 weeks, remained stable during the treatment period, and returned to baseline level 2 weeks after discontinuation of icodextrin. Serum osmolarity increased during the use of icodextrin by approximately 5 mOsm/L. No statistically significant relationship was found between plasma oligosaccharides and net UF. Peritoneal absorption of icodextrin (36.3% ± 5.1% at day 3,42.2% ± 5.9% at week 4, and 38.0% ± 6.3% at week 6) and peritoneal clearance of icodextrin (10.1 mL/minute at day 3,10.1 mL/min at week 4, and 10.3 mL/min at week 6) showed no major change over time. Serum sodium and serum chloride both decreased by 5 mEq/L with icodextrin but remained within the normal range during the treatment period and returned to baseline levels immediately after discontinuation. No serious adverse events were observed during the study.
♦ Conclusion
The results of this study do not support the hypothesis that an increased blood oligosaccharide level and the concomitant elevation in serum osmolarity have a negative impact on peritoneal UF. Therefore, the increase in plasma oligosaccharides appears to be too small to be of clinical significance.
MistryC, GokalR, PeersE. MIDAS Study Group: A randomized multicenter clinical trial comparing isoosmolar icodextrin with hyperosmolar glucose solution in CAPD. Kidney Int1994; 46:496–503.
2.
MistryCD, MallickNP, GokalR. The advantage of glucose polymer as an osmotic agent in continuous peritoneal dialysis. Proc Eur Dial Transplant Assoc Eur Ren Assoc1985; 22:415–20.
3.
MoberlyJB, MujaisS, GehrT, HamburgerR, SpragueS, KucharskiA. Pharmacokinetics of icodextrin in peritoneal dialysis patients. Kidney Int Suppl2002; 81:S23–33.
4.
MistryCD, GokalR. Can ultrafiltration occur with a hypo-osmolar solution in peritoneal dialysis? The role for colloid osmosis. Clin Sci1993; 85:495–500.
5.
RippeB, LevinL. Computer simulations of ultrafiltration profiles for an icodextrin-based peritoneal fluid in CAPD. Kidney Int2000; 57:2546–56.
6.
MistryC, MallickN, GokalR. Ultrafiltration with an isosmotic solution during long peritoneal dialysis exchanges. Lancet1987; 2:178–82.
7.
DaviesDS. Kinetics of icodextrin. Perit Dial Int1994; 14(Suppl 2):S45–50.
8.
PosthumaN, ter WeePM, DonkerAJ, OePL, van DorpW, PeersEM. Serum disaccharides and osmolality in CCPD patients using icodextrin or glucose as daytime dwell. Perit Dial Int1997; 17:602–7.
9.
MistryCD, GokalR. Icodextrin in peritoneal dialysis: early development and clinical use. Perit Dial Int1994; 14(Suppl 2):S13–21.
10.
WangT, HeimbürgerO, ChengH, WaniewskiJ, BergströmJ, LindholmB. Peritoneal fluid and solute transport with different glucose formulations. Perit Dial Int1998; 18:193–203.
11.
WangT, ChengH, HeimbürgerO, WaniewskiJ, BergströmJ, LindholmB. Effect of peritonitis on peritoneal transport characteristics: glucose solution versus polyglucose solution. Kidney Int2000; 57:1704–13.
12.
de WaartDR, ZweersMM, StruijkDG, KredietRT. Icodextrin degradation products in spent dialysate of CAPD patients and the rat, and its relation with dialysate osmolality. Perit Dial Int2001; 21:269–74.
13.
PosthumaN, ter WeeP, DonkerA, OeP, PeersE, VerbrughH. Assessment of the effectiveness, safety, and biocompatibility of icodextrin in automated peritoneal dialysis. Perit Dial Int2000; 20(Suppl 2):S106–13.
14.
ICH Harmonised tripartite guideline. Clinical safety data management: definitions and standards for expedited reporting. Step 4; 27 October 1994. Available from: URL: http://www.ich.org/
15.
WolfsonM, PirainoB, HamburgerRJ, MortonR, for the Icodextrin Study Group. A randomized controlled trial to evaluate the efficacy and safety of icodextrin in peritoneal dialysis. Am J Kidney Dis2002; 40:1055–65.
16.
MujaisS, VoneshE. Profiling of peritoneal ultrafiltration Metabolic and laboratory effects of icodextrin. Kidney Int2002; 62(Suppl 81):S17–22.
17.
WoodrowG, StablesG, OldroydB, GibsonJ, TurneyJ, BrownjohnA. Comparison of icodextrin and glucose solutions for the daytime dwell in automated peritoneal dialysis. Nephrol Dial Transplant1999; 14:1530–5.
18.
PlumJ, GentileS, VergerC, BrunkhorstR, BahnerU, PeetersJ. Efficacy and safety of a 7.5% icodextrin peritoneal dialysis solution in patients treated with automated peritoneal dialysis — a prospective, randomized, multicenter trial. Am J Kidney Dis2002; 39: 862–71.
19.
GokalR, MoberlyJ, LindholmB, MujaisS. Metabolic and laboratory effects of icodextrin. Kidney Int Suppl2002; 81:S62–71.
